Lipids & Metabolic

The U.S. Food and Drug Administration approved the country’s first interoperable insulin pump Feb. 14, reporting the technology will help diabetics better individualize their treatment regimens.

Results from President Donald Trump’s latest physical, released Feb. 14., reveal the president’s overall cholesterol has improved since last year’s check-up, according to the Associated Press. But Trump has also gained weight and is now classified as obese, which could raise his already elevated risk for heart disease.

A 73-year-old Florida man posing as a fake doctor was arrested after he diagnosed an undercover cop with diabetes and high cholesterol and offered to “cure” the man with a $2,000 autologous blood transfusion, the Miami Herald reported Feb. 13.

“Rather than bringing in many additional statin candidates, this testing should serve as a decision aid to ‘de-risk’ certain patients and distinguish those who may benefit from preventive pharmacologic therapies," Johns Hopkins researchers wrote in the Annals of Internal Medicine.

A capsule no bigger than a blueberry could be the future of insulin delivery for type 1 diabetics, according to researchers at MIT.

UnitedHealthcare partnered with Medtronic Feb. 1 to make the device company’s MiniMed 670G insulin pump system its preferred pump for diabetics aged 7 and up—a move the Juvenile Diabetes Research Foundation (JDRF) calls “an unacceptable step backward” and says effectively limits patients’ choices to one product.

Fast-acting, inhalable insulin is growing in popularity among American adults with diabetes, local Minnesota outlet Fox 9 reported Feb. 1.

Statin therapy reduces the risk of major cardiovascular events across all age ranges, even among people older than 75, according to a meta-analysis published in The Lancet.

A new study in JAMA Cardiology found the most avid exercisers—averaging eight hours per week of vigorous exercise—showed greater levels of coronary artery calcium (CAC). Nevertheless, they were less prone to dying over the average follow-up of 10.4 years compared to participants who exercised less, suggesting they can safely continue their workout regimens. 

A health plan-wide intervention to switch diabetic patients from costly new insulin products to older, more affordable drugs resulted in a marginal increase in hemoglobin A1c (hbA1c) levels but didn’t change the rate of hospital visits for dangerously high or low blood sugar, researchers reported Jan. 29 in JAMA.

The blood sugar drug dapagliflozin was declared noninferior to placebo in the recent DECLARE-TIMI 58 trial, and while the medication failed to lower rates of major adverse cardiovascular events (MACE) in subjects, it did reduce rates of CV-related death and hospitalizations for heart failure.

Although the 2013 American College of Cardiology and American Heart Association cholesterol guidelines expanded indications for statin use in heart patients, few primary care providers (PCPs) are prescribing more of the medication, researchers reported Jan. 25 in the Journal of the American Heart Association.